Nadroparin or fondaparinux for thromboprophylaxis after ankle/foot fracture managed conservatively .
This report has been verified
by one or more authors of the
original publication.
Nadroparin or fondaparinux versus no thromboprophylaxis in patients immobilised in a below-knee plaster cast (PROTECT): A randomised controlled trial
Injury. 2017 Apr;48(4):936-940467 patients managed with a below-knee plaster cast for a foot or ankle fracture were randomized to either subcutaneous nadroparin 2850IE daily, subcutaneous fondaparinux 2.5mg daily, or no thromboprophylaxis intervention (control). Patients were screened during follow-up for cases of deep vein thrombosis and pulmonary embolism. Results demonstrated significantly lower rates of deep vein thrombosis in both the nadroparin and fondaparinux groups compared to the control group. All but two cases of DVT in the control group were asymptomatic; symptomatic patients had pulmonary embolism confirmed by CT angiography.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
